Close Menu

NEW YORK – In vitro diagnostic firm Sebia announced Tuesday it is partnering with Sanofi to develop a diagnostic test to mitigate possible interference from Sanofi's investigational antibody, isatuximab, in patients with multiple myeloma.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.